Psychosomatics
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Psychosomatics 50:159-161, March-April 2009
doi: 10.1176/appi.psy.50.2.159
© 2009 Academy of Psychosomatic Medicine
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Pasquini, M.
* Articles by Biondi, M.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Pasquini, M.
* Articles by Biondi, M.
Related Collections
* Atypical Neuroleptics
* Sleep Disorders
* Syndromes Secondary to General Medical Disorders

Case Report

Quetiapine for Tamoxifen-Induced Insomnia in Women With Breast Cancer

Massimo Pasquini, M.D., Azzurra Speca, M.D., and Massimo Biondi, M.D.

Received September 7, 2007; revised December 9, 2007; accepted January 11, 2008. From the Dept. of Psychiatric Science and Psychological Medicine, Psycho-oncology Unit, SAPIENZA University of Rome (Italy). Send correspondence and reprint requests to Massimo Pasquini, M.D., Dept. of Psychiatric Science and Psychological Medicine, Psycho-oncology Unit, SAPIENZA, University of Rome, Viale dell’Università 30, 00185, Rome, Italy. e-mail: massimo.pasquini{at}uniroma1.it
© 2009 The Academy of Psychosomatic Medicine

BACKGROUND: Insomnia is a frequent adverse effect reported by women taking tamoxifen, an estradiol receptor-antagonist, for breast cancer. OBJECTIVE: The authors report on six patients treated with quetiapine, an atypical antipsychotic, for tamoxifen-related insomnia without depression. METHOD: Quetiapine was started at 25 mg/day 1 hour before bedtime; dose adjustments upward were made in 25-mg increments, titrated to a maximum dose of 100 mg according to therapeutic response and tolerance. RESULTS: Five of the six women showed a prompt improvement of their insomnia; this effect was maintained after 6 weeks of treatment. DISCUSSION: Quetiapine might improve sleep alterations because of its high affinity for serotonergic receptors, enhancing central serotonergic neurotransmission, thus possibly decreasing excitatory glutamatergic transmission.







Get information about faster international access.

Privacy Policy

Copyright © 2009 Academy of Psychosomatic Medicine. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. Academy of Psychosomatic Medicine
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org